Skip to main content
NCBI home page
Brain Pathology logoLink to Brain Pathology
. 2006 Apr 5;15(2):149–158. doi: 10.1111/j.1750-3639.2005.tb00512.x

Cyclopentenone Eicosanoids as Mediators of Neurodegeneration: A Pathogenic Mechanism of Oxidative Stress‐Mediated and Cyclooxygenase‐Mediated Neurotoxicity

Erik S Musiek 1, Ginger L Milne 1, Beth Ann McLaughlin 1,3, Jason D Morrow 1,2,✉
PMCID: PMC2881556  NIHMSID: NIHMS81251  PMID: 15912888

Abstract

The activation of cyclooxygenase enzymes in the brain has been implicated in the pathogenesis of numerous neurodegenerative conditions. Similarly, oxidative stress is believed to be a major contributor to many forms of neurodegeneration. These 2 distinct processes are united by a common characteristic: the generation of electrophilic cyclopentenone eicosanoids. These cyclopentenone compounds are defined structurally by the presence of an unsaturated carbonyl moiety in their prostane ring, and readily form Michael adducts with cellular thiols, including those found in glutathione and proteins. The cyclopentenone prostaglandins (PGs) PGA2, PGJ2, and 15‐deoxy‐Δ12,14 PGJ2, enzymatic products of cyclooxygenase‐mediated arachidonic acid metabolism, exert a complex array of potent neurodegenerative, neuroprotective, and anti‐inflammatory effects. Cyclopentenone isoprostanes (A2/J2‐IsoPs), products of non‐enzymatic, free radical‐mediated arachidonate oxidation, are also highly bioactive, and can exert direct neurodegenerative effects. In addition, cyclopentenone products of docosahexaenoic acid oxidation (cyclopentenone neuroprostanes) are also formed abundantly in the brain. For the first time, the formation and biological actions of these various classes of reactive cyclopentenone eicosanoids are reviewed, with emphasis on their potential roles in neurodegeneration. The accumulating evidence suggests that the formation of cyclopentenone eicosanoids in the brain may represent a novel pathogenic mechanism, which contributes to many neurodegenerative conditions.

Full Text

The Full Text of this article is available as a PDF (212.3 KB).

REFERENCES

  • 1. Abdel‐Halim MS, Lunden I, Cseh G, Anggard E (1980) Prostaglandin profiles in nervous tissue and blood vessels of the brain of various animals. Prostaglandins 19:249–258. [DOI] [PubMed] [Google Scholar]
  • 2. Akbar M, Kim HY (2002) Protective effects of docosahexaenoic acid in staurosporine‐induced apoptosis: involvement of phosphatidylinositol‐3 kinase pathway. J Neurochem 82:655–665. [DOI] [PubMed] [Google Scholar]
  • 3. Akiyama H, McGeer PL (2004) Specificity of mechanisms for plaque removal after A beta immunotherapy for Alzheimer disease. Nat Med 10:117–118. [DOI] [PubMed] [Google Scholar]
  • 4. Alvarez‐Maqueda M, El Bekay R, Alba G, Monteseirin J, Chacon P, Vega A, Martin‐Nieto J, Bedoya FJ, Pintado E, Sobrino F (2004) 15‐deoxy‐delta 12,14‐prostaglandin J2 induces heme oxygenase‐1 gene expression in a reactive oxygen species‐dependent manner in human lymphocytes. J Biol Chem 279:21929–1937. [DOI] [PubMed] [Google Scholar]
  • 5. Aoun P, Watson DG, Simpkins JW (2003) Neuroprotective effects of PPARg agonists against oxidative insults in HT‐22 cells. Eur J Pharmacol 472:65–71. [DOI] [PubMed] [Google Scholar]
  • 6. Atsmon J, Freeman ML, Meredith MJ, Sweet‐man BJ, Roberts LJ (1990) Conjugation of 9‐deoxy‐delta‐9‐delta 12‐(E)‐prostaglandin D2 with intracellular glutathione and enhancement of its anti‐proliferative activity by glutathione depletion. Cancer Res 50:1879–1885. [PubMed] [Google Scholar]
  • 7. Atsmon J, Sweetman BJ, Baertschi SW, Harris TM, Roberts LJ, 2nd (1990) Formation of thiol conjugates of 9‐deoxy‐delta 9, delta 12(E)‐prostaglandin D2 and delta 12(E)‐prostaglandin D2. Biochemistry 29:3760–3765. [DOI] [PubMed] [Google Scholar]
  • 8. Bayir H, Kagan VE, Tyurina YY, Tyurin V, Ruppel RA, Adelson PD, Graham SH, Janesko K, Clark RS, Kochanek PM (2002) Assessment of antioxidant reserves and oxidative stress in cerebrospinal fluid after severe traumatic brain injury in infants and children. Pediatric Res 51:571–578. [DOI] [PubMed] [Google Scholar]
  • 9. Beal MF (1995) Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 38:357–66. [DOI] [PubMed] [Google Scholar]
  • 10. Bell‐Parikh LC, Ide T, Lawson JA, McNamara P, Reilly M, FitzGerald GA (2003) Biosynthesis of 15‐deoxy‐delta12,14‐PGJ2 and the ligation of PPARy. J Clin Invest 112:945–955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Bogaards JJ, Venekamp JC, van Bladeren PJ (1997) Stereoselective conjugation of prostaglandin A2 and prostaglandin J2 with glutathione, catalyzed by the human glutathione S‐transferases A1–1, A2–2, M1a‐1a, and P1–1. Chem Res Toxicol 10:310–317. [DOI] [PubMed] [Google Scholar]
  • 12. Bruckner SR, Perry G, Estus S (2003) 4‐hydroxynonenal contributes to NGF withdrawal‐induced neuronal apoptosis. J Neurochem 85:999–1005. [DOI] [PubMed] [Google Scholar]
  • 13. Calon F, Lim GP, Yang F, Morihara T, Teter B, Ubeda O, Rostaing P, Triller A, Salem N, Jr. , Ashe KH, Frautschy SA, Cole GM (2004) Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 43:633–645. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Castano A, Herrera AJ, Cano J, Machado A (2002) The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh‐TNF‐alpha, IL‐1beta and IFN‐gamma. J Neurochem 81:150–157. [DOI] [PubMed] [Google Scholar]
  • 15. Castrillo A, Traves PG, Martin‐Sanz P, Parkinson S, Parker PJ, Bosca L (2003) Potentiation of protein kinase C zeta activity by 15‐deoxy‐delta(12,14)‐prostaglandin J(2) induces an imbalance between mitogen‐activated protein kinases and NF‐kappa B that promotes apoptosis in macrophages. Mol Cell Bio 123:1196–1208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Cernuda‐Morollon E, Pineda‐Molina E, Canada FJ, Perez‐Sala D (2001) 15‐Deoxy‐Delta 12,14‐prostaglandin J2 inhibition of NF‐kappaB‐DNA binding through covalent modification of the p50 subunit. J Biol Chem 276:35530–35536. [DOI] [PubMed] [Google Scholar]
  • 17. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM (2001) PPAR‐gamma dependent and independent effects on macrophage‐gene expression in lipid metabolism and inflammation. Nat Med 7:48–52. [DOI] [PubMed] [Google Scholar]
  • 18. Chen H, Zhang SM, Hernan MA, Schwarzschild MA, Willett WC, Colditz GA, Speizer FE, Ascherio A (2003) Nonsteroidal anti‐inflammatory drugs and the risk of Parkinson Disease. Arch Neurol 60:1059–1064. [DOI] [PubMed] [Google Scholar]
  • 19. Chen Y, Morrow JD, Roberts LJ, 2nd (1999) Formation of reactive cyclopentenone compounds in vivo as products of the isoprostane pathway. J Biol Chem 274:10863–10868. [DOI] [PubMed] [Google Scholar]
  • 20. Chen Y, Zackert WE, Roberts LJ, 2nd , Morrow JD (1999) Evidence for the formation of a novel cyclopentenone isoprostane, 15‐A2t‐isoprostane (8‐iso‐prostaglandin A2) in vivo. Biochim Biophys Acta 1436:550–556. [DOI] [PubMed] [Google Scholar]
  • 21. Chiarugi A (2002) Characterization of the molecular events following impairment of NF‐kappaB‐driven transcription in neurons. Brain Res Mol Brain Res 109:179–188. [DOI] [PubMed] [Google Scholar]
  • 22. Clay CE, Monjazeb A, Thorburn J, Chilton FH, High KP (2002) 15‐Deoxy‐delta 12,14‐prostaglandin J2‐induced apoptosis does not require PPARy in breast cancer cells. J Lipid Res 43:1818–1828. [DOI] [PubMed] [Google Scholar]
  • 23. Culmsee C, Siewe J, Junker V, Retiounskaia M, Schwarz S, Camandola S, El‐Metainy S, Behnke H, Mattson MP, Krieglstein J (2003) Reciprocal inhibition of p53 and nuclear factor‐kappaB transcriptional activities determines cell survival or death in neurons. J Neurosci 23:8586–8595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. de Bittencourt PI, Jr. , Miyasaka CK, Curi R, Williams JF (1998) Effects of the antiproliferative cyclopentenone prostaglandin A1 on glutathione metabolism in human cancer cells in culture. Biochem Mol Biol Int 45:1255–1264. [DOI] [PubMed] [Google Scholar]
  • 25. Drachman DB, Frank K, Dykes‐Hoberg M, Teismann P, Almer G, Przedborski S, Rothstein JD (2002) Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol 52:771–778. [DOI] [PubMed] [Google Scholar]
  • 26. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, Triarhou LC, Chernet E, Perry KW, Nelson DL, Luecke S, Phebus LA, Bymaster FP, Paul SM (2001) Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A 98:14669–14674. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Fam SS, Murphey LJ, Terry ES, Zackert WE, Chen Y, Gao L, Pandalai S, Milne GL, Roberts LJ, Porter NA, Montine TJ, Morrow JD (2002) Formation of highly reactive A‐ring and J‐ring isoprostane‐like compounds (A4/J4‐neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem 277:36076–36084. [DOI] [PubMed] [Google Scholar]
  • 28. Feng ZH, Wang TG, Li DD, Fung P, Wilson BC, Liu B, Ali SF, Langenbach R, Hong JS (2002) Cyclooxygenase‐2‐deficient mice are resistant to 1‐methyl‐4‐phenyl 1, 2, 3, 6‐tetrahydropyridine‐induced damage of dopaminergic neurons in the substantia nigra. Neurosci Lett 329:354–358. [DOI] [PubMed] [Google Scholar]
  • 29. Fitzpatrick FA, Wynalda MA (1983) Albumincatalyzed metabolism of prostaglandin D2. Identification of products formed in vitro. J Biol Chem 258:11713–11718. [PubMed] [Google Scholar]
  • 30. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM (1995) 15‐Deoxy‐delta 12, 14‐prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83:803–812. [DOI] [PubMed] [Google Scholar]
  • 31. Frolich JC, Sweetman BJ, Carr K, Hollifield JW, Oates JA (1975) Assessment of the levels of pga2 in human plasma by gas chromatography‐mass spectrometry. Prostaglandins 10:185–195. [DOI] [PubMed] [Google Scholar]
  • 32. Fukushima M, Kato T, Ota K, Arai Y, Narumiya S, Hayaishi O (1982) 9‐deoxy‐delta 9‐prostaglandin D2, a prostaglandin D2 derivative with potent antineoplastic and weak smooth musclecontracting activities. Biochem Biophy Res Comm 109:626–633. [DOI] [PubMed] [Google Scholar]
  • 33. Gebicke‐Haerter PJ (2001) Microglia in neurodegeneration: molecular aspects. Microsc Res Tech 54:47–58. [DOI] [PubMed] [Google Scholar]
  • 34. Graham SH, Hickey RW (2003) Cyclooxygenases in central nervous system diseases: a special role for cyclooxygenase 2 in neuronal cell death.(see comment)(comment). Arch Neurol 60:628–630. [DOI] [PubMed] [Google Scholar]
  • 35. Greco A, Minghetti L, Sette G, Fieschi C, Levi G (1999) Cerebrospinal fluid isoprostane shows oxidative stress in patients with multiple sclerosis. Neurology 53:1876–1879. [DOI] [PubMed] [Google Scholar]
  • 36. Hamberg M, Samuelsson B (1966) Prostaglandins in human seminal plasma. Prostaglandins and related factors 46. J Biol Chem 241:257–263. [PubMed] [Google Scholar]
  • 37. Heneka MT, Feinstein DL, Galea E, Gleichmann M, Wullner U, Klockgether T (1999) Peroxisome proliferator‐activated receptor gamma agonists protect cerebellar granule cells from cytokine‐induced apoptotic cell death by inhibition of inducible nitric oxide synthase. J Neuroimmunology 100:156–168. [DOI] [PubMed] [Google Scholar]
  • 38. Heneka MT, Klockgether T, Feinstein DL (2000) Peroxisome proliferator‐activated receptor‐gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J Neurosci 20:6862–6867. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Hirata Y, Hayashi H, Ito S, Kikawa Y, Ishibashi M, Sudo M, Miyazaki H, Fukushima M, Narumiya S, Hayaishi O (1988) Occurrence of 9–deoxy‐delta 9, delta 12–13,14–dihydroprostaglandin D2 in human urine. J Biol Chem 263:16619–16625. [PubMed] [Google Scholar]
  • 40. Homem de Bittencourt PI, Jr. , Curi R (2001) Antiproliferative prostaglandins and the MRP/GS‐X pump role in cancer immunosuppression and insight into new strategies in cancer gene therapy. Biochem Pharmacol 62:811–819. [DOI] [PubMed] [Google Scholar]
  • 41. Honn KV, Marnett LJ (1985) Requirement of a reactive alpha, beta‐unsaturated carbonyl for inhibition of tumor growth and induction of differentiation by “A” series prostaglandins. Biochem Biophys Res Comm 129:34–40. [DOI] [PubMed] [Google Scholar]
  • 42. Hortelano S, Castrillo A, Alvarez AM, Bosca L (2000) Contribution of cyclopentenone prostaglandins to the resolution of inflammation through the potentiation of apoptosis in activated macrophages. J Immunol 165:6525–6531. [DOI] [PubMed] [Google Scholar]
  • 43. Hubatsch I, Mannervik B, Gao L, Roberts LJ, Chen Y, Morrow JD (2002) The cyclopentenone product of lipid peroxidation, 15–A(2t)‐isopros‐tane (8–isoprostaglandin A(2)), is efficiently conjugated with glutathione by human and rat glutathione transferase A4–4. Chem Res Toxicol 15:1114–1118. [DOI] [PubMed] [Google Scholar]
  • 44. Hunot S, Hirsch EC (2003) Neuroinflammatory processes in Parkinson's disease. Ann Neurol 53 Suppl 3:S49–58. [DOI] [PubMed] [Google Scholar]
  • 45. Iadecola C, Niwa K, Nogawa S, Zhao X, Nagayama M, Araki E, Morham S, Ross ME (2001) Reduced susceptibility to ischemic brain injury and N‐methyl‐D‐aspartate‐mediated neurotoxicity in cyclooxygenase‐2‐deficient mice. Proc Natl Acad Sci U S A 98:1294–1299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46. in T'Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, Breteler MM, Stricker BH (2001) Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 345:1515–1521. [DOI] [PubMed] [Google Scholar]
  • 47. Iwamoto N, Kobayashi K, Kosaka K (1989) The formation of prostaglandins in the postmortem cerebral cortex of Alzheimer‐type dementia patients. J Neurol 236:80–84. [DOI] [PubMed] [Google Scholar]
  • 48. Janabi N (2002) Selective inhibition of cyclooxygenase‐2 expression by 15‐deoxy‐Delta(12,14) (12,14)‐prostaglandin J(2) in activated human astrocytes, but not in human brain macrophages. J Immunol 168:4747–4755. [DOI] [PubMed] [Google Scholar]
  • 49. Kaltschmidt B, Uherek M, Wellmann H, Volk B, Kaltschmidt C (1999) Inhibition of NF‐kappaB potentiates amyloid beta‐mediated neuronal apoptosis. Proc Natl Acad Sci U S A 96:9409–9414. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50. Kawamoto Y, Nakamura Y, Naito Y, Torii Y, Kumagai T, Osawa T, Ohigashi H, Satoh K, Imagawa M, Uchida K (2000) Cyclopentenone prostaglandins as potential inducers of phase II detoxification enzymes. 15‐deoxy‐delta(12,14)‐prostaglandin j2‐induced expression of glutathione S‐transfer‐ases. J Biol Chem 275:11291–11299. [DOI] [PubMed] [Google Scholar]
  • 51. Keelan JA, Sato TA, Marvin KW, Lander J, Gilmour RS, Mitchell MD (1999) 15‐Deoxy‐Delta(12,14)‐prostaglandin J(2), a ligand for peroxisome proliferator‐activated receptor‐gamma, induces apoptosis in JEG3 choriocarcinoma cells. Biochem Biophys Res Comm 262:579–585. [DOI] [PubMed] [Google Scholar]
  • 52. Kikawa Y, Narumiya S, Fukushima M, Wakatsuka H, Hayaishi O (1984) 9–Deoxy‐delta 9, delta 12–13,14–dihydroprostaglandin D2, a metabolite of prostaglandin D2 formed in human plasma. Proc Natl Acad Sci U S A 81:1317–1321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM (1995) A prostaglandin J2 metabolite binds peroxisome proliferator‐activated receptor gamma and promotes adipocyte differentiation. Cell 83:813–819. [DOI] [PubMed] [Google Scholar]
  • 54. Koizumi T, Negishi M, Ichikawa A (1992) Induction of heme oxygenase by delta 12‐prostaglandin J2 in porcine aortic endothelial cells. Prostaglandins 43:121–131. [DOI] [PubMed] [Google Scholar]
  • 55. Kondo M, Oya‐Ito T, Kumagai T, Osawa T, Uchida K (2001) Cyclopentenone prostaglandins as potential inducers of intracellular oxidative stress. J Biol Chem 276:12076–12083. [DOI] [PubMed] [Google Scholar]
  • 56. Kondo M, Shibata T, Kumagai T, Osawa T, Shibata N, Kobayashi M, Sasaki S, Iwata M, Noguchi N, Uchida K (2002) 15‐Deoxy‐Delta(12,14)‐prostaglandin J(2): the endogenous electrophile that induces neuronal apoptosis. Proc Natl Acad Sci U S A 99:7367–7372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57. Koppal T, Petrova TV, Van Eldik LJ (2000) Cyclopentenone prostaglandin 15‐deoxy‐Delta(12,14)‐prostaglandin J(2) acts as a general inhibitor of inflammatory responses in activated BV‐2 microglial cells. Brain Res 867:115–121. [DOI] [PubMed] [Google Scholar]
  • 58. Kraft AD, Johnson DA, Johnson JA (2004) Nuclear factor E2‐related factor 2‐dependent antioxidant response element activation by tertbutylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult. J Neurosci 24:1101–1112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59. Kruman I, Bruce‐Keller AJ, Bredesen D, Waeg G, Mattson MP (1997) Evidence that 4‐hydroxynonenal mediates oxidative stress‐induced neuronal apoptosis. J Neurosci 17:5089–5100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60. Lee JB, Crowshaw K, Takman BH, Attrep KA, Gougoutas JZ (1967) The identification of prostaglandin E2, F2alpha and A2 from rabbit kidney medulla. Biochem J 105:1251–1260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61. Lee JM, Shih AY, Murphy TH, Johnson JA (2003) NF‐E2‐related factor‐2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons. J Biol Chem 278:37948–37956. [DOI] [PubMed] [Google Scholar]
  • 62. Lennon AM, Ramauge M, Dessouroux A, Pierre M (2002) MAP kinase cascades are activated in astrocytes and preadipocytes by 15–de‐oxy‐Delta(12–14)‐prostaglandin J(2)and the thiazolidinedione ciglitazone through peroxisome proliferator activator receptor gamma‐independent mechanisms involving reactive oxygenated species. J Biol Chem 277:29681–29685. [DOI] [PubMed] [Google Scholar]
  • 63. Levonen AL, Dickinson DA, Moellering DR, Mulcahy RT, Forman HJ, Darley‐Usmar VM (2001) Biphasic effects of 15‐deoxy‐delta(12,14)‐prostaglandin J(2) on glutathione induction and apoptosis in human endothelial cells. Arterioscler Thromb Vasc Biol 21:1846–1851. [DOI] [PubMed] [Google Scholar]
  • 64. Levonen AL, Landar A, Ramachandran A, Ceaser EK, Dickinson DA, Zanoni G, Morrow JD, Darley‐Usmar VM (2004) Cellular mechanisms of redoxcell signaling: role of cysteine modification in controlling antioxidant defenses in response to electrophilic lipid oxidation products. Biochem J 378:373–382. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65. Li L, Tao J, Davaille J, Feral C, Mallat A, Rieusset J, Vidal H, Lotersztajn S (2001) 15‐deoxy‐Delta 12,14‐prostaglandin J2 induces apoptosis of human hepatic myofibroblasts. A pathway involving oxidative stress independently of peroxisome‐proliferator‐activated receptors. J Biol Chem 276:38152–38158. [DOI] [PubMed] [Google Scholar]
  • 66. Li Y, Maher P, Schubert D (1997) A role for 12‐lipoxygenase in nerve cell death caused by glutathione depletion. Neuron 19:453–463. [DOI] [PubMed] [Google Scholar]
  • 67. Lim SY, Jang JH, Na HK, Lu SC, Rahman I, Surh YJ (2004) 15‐Deoxy‐Delta12,14‐prostaglandin J(2) protects against nitrosative PC1 2 cell death through up‐regulation of intracellular glutathione synthesis. J Biol Chem 279:46263–46270. [DOI] [PubMed] [Google Scholar]
  • 68. Liu JD, Lin SY, Ho YS, Pan S, Hung LF, Tsai SH, Lin JK, Liang YC (2003) Involvement of c‐jun N‐terminal kinase activation in 15‐deoxy‐delta 12,14‐prostaglandin J2‐and prostaglandin A1‐induced apoptosis in AGS gastric epithelial cells. Mol Carcinogenesis 37:16–24. [DOI] [PubMed] [Google Scholar]
  • 69. Maggi LB, Jr. , Sadeghi H, Weigand C, Scarim AL, Heitmeier MR, Corbett JA (2000) Anti‐inflammatory actions of 15‐deoxy‐delta 12,14‐prostaglandin J2 and troglitazone: evidence for heat shock‐dependent and‐independent inhibition of cytokine‐induced inducible nitric oxide synthase expression. Diabetes 49:346–355. [DOI] [PubMed] [Google Scholar]
  • 70. Mattson MP, Camandola S (2001) NF‐kappaB in neuronal plasticity and neurodegenerative disorders. J Clin Invest 107:247–254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71. McGeer PL, McGeer EG (1998) Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions. Alz Dis Assoc Dis 12 Suppl 2:S1–6. [PubMed] [Google Scholar]
  • 72. McLaughlin B, Hartnett KA, Erhardt JA, Legos JJ, White RF, Barone FC, Aizenman E (2003) Caspase 3 activation is essential for neuroprotection in preconditioning. Proc Natl Acad Sci U S A 100:715–720. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73. Meffert MK, Baltimore D (2005) Physiological functions for brain NF‐kappaB. Trends Neurosci 28:37–43. [DOI] [PubMed] [Google Scholar]
  • 74. Milatovic D, Zaja‐Milatovic S, Montine KS, Horner PJ, Montine TJ (2003) Pharmacologic suppression of neuronal oxidative damage and dendritic degeneration following direct activation of glial innate immunity in mouse cerebrum. J Neurochem 87:1518–526. [DOI] [PubMed] [Google Scholar]
  • 75. Milatovic D, Zhang Y, Olson SJ, Montine KS, Roberts LJ, 2nd , Morrow JD, Montine TJ, Dermody TS, Valyi‐Nagy T (2002) Herpes simplex virus type 1 encephalitis is associated with elevated levels of F2‐isoprostanes and F4‐neuroprostanes. J Neurovirology 8:295–305. [DOI] [PubMed] [Google Scholar]
  • 76. Milne GL, Musiek ES, Morrow JD (2005) The cyclopentenone (a(2)/j(2)) isoprostanes‐unique, highly reactive products of arachidonate peroxidation. Antioxid Redox Signaling 7:210–220. [DOI] [PubMed] [Google Scholar]
  • 77. Milne GL, Zanoni G, Porta A, Sasi S, Vidari G, Musiek ES, Freeman ML, Morrow JD (2004) The cyclopentenone product of lipid peroxidation, 15‐A2t‐isoprostane, is efficiently metabolized by HepG2 cells via conjugation with glutathione. Chem Res Toxicol 17:17–25. [DOI] [PubMed] [Google Scholar]
  • 78. Minghetti L (2004) Cyclooxygenase‐2 (COX‐2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 63:901–910. [DOI] [PubMed] [Google Scholar]
  • 79. Minghetti L, Greco A, Cardone F, Puopolo M, Ladogana A, Almonti S, Cunningham C, Perry VH, Pocchiari M, Levi G (2000) Increased brain synthesis of prostaglandin E2 and F2‐isoprostane in human and experimental transmissible spongiform encephalopathies. J Neuropath Exp Neurol 59:866–871. [DOI] [PubMed] [Google Scholar]
  • 80. Montine TJ, Beal MF, Cudkowicz ME, O'Donnell H, Margolin RA, McFarland L, Bachrach AF, Zackert WE, Roberts LJ, Morrow JD (1999) Increased CSF F2‐isoprostane concentration in probable AD. Neurology 52:562–565. [DOI] [PubMed] [Google Scholar]
  • 81. Montine TJ, Beal MF, Robertson D, Cudkowicz ME, Biaggioni I, O'Donnell H, Zackert WE, Roberts LJ, Morrow JD (1999) Cerebrospinal fluid F2‐iso‐prostanes are elevated in Huntington's disease. Neurology 52:1104–1105. [DOI] [PubMed] [Google Scholar]
  • 82. Montine TJ, Kaye JA, Montine KS, McFarland L, Morrow JD, Quinn JF (2001) Cerebrospinal fluid Aβ42, tau, and F2‐isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age‐matched controls. Arch Pathol Lab Med 125:510–512. [DOI] [PubMed] [Google Scholar]
  • 83. Montine TJ, Markesbery WR, Morrow JD, Roberts LJ, 2nd (1998) Cerebrospinal fluid F2‐isoprostane levels are increased in Alzheimer's disease. Ann Neurol 44:410–413. [DOI] [PubMed] [Google Scholar]
  • 84. Montine TJ, Milatovic D, Gupta RC, Valyi‐Nagy T, Morrow JD, Breyer RM (2002) Neuronal oxidative damage from activated innate immunity is EP2 receptor‐dependent. J Neurochem 83:463–470. [DOI] [PubMed] [Google Scholar]
  • 85. Montine TJ, Montine KS, Reich EE, Terry ES, Porter NA, Morrow JD (2003) Antioxidants significantly affect the formation of different classes of isoprostanes and neuroprostanes in rat cerebral synaptosomes. Biochem Pharmacol 65:611–617. [DOI] [PubMed] [Google Scholar]
  • 86. Montine TJ, Sidell KR, Crews BC, Markesbery WR, Marnett LJ, Roberts LJ, 2nd , Morrow JD (1999) Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology 53:1495–1498. [DOI] [PubMed] [Google Scholar]
  • 87. Moos PJ, Edes K, Fitzpatrick FA (2000) Inactivation of wild‐type p53 tumor suppressor by electrophilic prostaglandins. Proc Natl Acad Sci U S A 97:9215–9220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88. Mori TA, Beilin LJ (2004) Omega‐3 fatty acids and inflammation. Curr Atheroscler Rep 6:461–467. [DOI] [PubMed] [Google Scholar]
  • 89. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Wilson RS, Aggarwal N, Schneider J (2003) Consumption of fish and n‐3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 60:940–946. [DOI] [PubMed] [Google Scholar]
  • 90. Morrow JD, Awad JA, Boss HJ, Blair IA, Roberts LJ, 2nd (1992) Non‐cyclooxygenase‐derived prostanoids (F2‐isoprostanes) are formed in situ on phospholipids. Proc Natl Acad Sci U S A 89:10721–10725. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91. Morrow JD, Harris TM, Roberts LJ, 2nd (1990) Noncyclooxygenase oxidative formation of a series of novel prostaglandins: analytical ramifications for measurement of eicosanoids.(erratum appears in Analyt Biochem 1990 Apr;186(1):184–5). Analyt Biochem 184:1–10. [DOI] [PubMed] [Google Scholar]
  • 92. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ, 2nd (1990) A series of prostaglandin F2‐like compounds are produced in vivo in humans by a non‐cyclooxygenase, free radicalcatalyzed mechanism. Proc Natl Acad Sci U S A 87:9383–9387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93. Morrow JD, Minton TA, Mukundan CR, Campbell MD, Zackert WE, Daniel VC, Badr KF, Blair IA, Roberts LJ, 2nd (1994) Free radical‐induced generation of isoprostanes in vivo. Evidence for the formation of D‐ring and E‐ring isoprostanes. J Biol Chem 269:4317–4326. [PubMed] [Google Scholar]
  • 94. Morrow JD, Roberts LJ, 2nd (2001) Lipid‐Derived Autocoids: Eicosanoids and Platelet Activating Factor. In Goodman & Gilman's The Pharmcological Basis of Therapeutics, Hardman JG, Limbird LE, Gilman AG (Eds), 10th Edition, Chapter 26, pp. 669–87, McGraw‐Hill: New York . [Google Scholar]
  • 95. Morrow JD, Roberts LJ, 2nd (1999) Mass spectrometric quantification of F2‐isoprostanes in biological fluids and tissues as measure of oxidant stress. Meth Enzymol 300:3–12. [DOI] [PubMed] [Google Scholar]
  • 96. Morrow JD, Scruggs J, Chen Y, Zackert WE, Roberts LJ, 2nd (1998) Evidence that the E2‐iso‐prostane, 15‐E2t‐isoprostane (8‐iso‐prostaglan‐din E2) is formed in vivo. J Lipid Res 39:1589–1593. [PubMed] [Google Scholar]
  • 97. Mullally JE, Moos PJ, Edes K, Fitzpatrick FA (2001) Cyclopentenone prostaglandins of the J series inhibit the ubiquitin isopeptidase activity of the proteasome pathway. J Biol Chem 276:30366–30373. [DOI] [PubMed] [Google Scholar]
  • 98. Murphy TH, Miyamoto M, Sastre A, Schnaar RL, Coyle JT (1989) Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress. Neuron 2:1547–1558. [DOI] [PubMed] [Google Scholar]
  • 99. Narumiya S, Fukushima M (1986) Site and mechanism of growth inhibition by prostaglandins. I. Active transport and intracellular accumulation of cyclopentenone prostaglandins, a reaction leading to growth inhibition. J Pharmacol Exp Ther 239:500–505. [PubMed] [Google Scholar]
  • 100. Narumiya S, Ohno K, Fukushima M, Fujiwara M (1987) Site and mechanism of growth inhibition by prostaglandins. III. Distribution and binding of prostaglandin A2 and delta 12‐prostaglandin J2 in nuclei. J Pharmacol Exp Ther 242:306–311. [PubMed] [Google Scholar]
  • 101. Nencioni A, Lauber K, Grunebach F, Brugger W, Denzlinger C, Wesselborg S, Brossart P (2002) Cyclopentenone prostaglandins induce caspase activation and apoptosis in dendritic cells by a PPAR‐gamma‐independent mechanism: regulation by inflammatory and T cell‐derived stimuli. Exp Hematology 30:1020–1028. [DOI] [PubMed] [Google Scholar]
  • 102. Nogawa S, Zhang F, Ross ME, Iadecola C (1997) Cyclo‐oxygenase‐2 gene expression in neurons contributes to ischemic brain damage. J Neurosci 17:2746–2755. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103. Ogorochi T, Narumiya S, Mizuno N, Yamashita K, Miyazaki H, Hayaishi O (1984) Regional distribution of prostaglandins D2, E2, and F2 alpha and related enzymes in postmortem human brain. J Neurochem 43:71–82. [DOI] [PubMed] [Google Scholar]
  • 104. Oka A, Takashima S (1997) Induction of cyclo‐oxygenase 2 in brains of patients with Down's syndrome and dementia of Alzheimer type: specific localization in affected neurones and axons. Neuroreport 8:1161–1164. [DOI] [PubMed] [Google Scholar]
  • 105. Ou JJ, Zhang Y, Montine TJ (2002) In vivo assessment of lipid peroxidation products associated with age‐related neurodegenerative diseases. Exp Neurol 175:363–369. [DOI] [PubMed] [Google Scholar]
  • 106. Pasinetti GM, Aisen PS (1998) Cyclooxygenase‐2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience 87:319–324. [DOI] [PubMed] [Google Scholar]
  • 107. Paumi CM, Wright M, Townsend AJ, Morrow CS (2003) Multidrug resistance protein (MRP) 1 and MRP3 attenuate cytotoxic and transactivating effects of the cyclopentenone prostaglandin, 15‐deoxy‐Delta(12,14) prostaglandin J2 in MCF7 breast cancer cells. Biochemistry 42:5429–5437. [DOI] [PubMed] [Google Scholar]
  • 108. Pepicelli O, Fedele E, Bonanno G, Raiteri M, Ajmone‐Cat MA, Greco A, Levi G, Minghetti L (2002) In vivo activation of N‐methyl‐D‐aspartate receptors in the rat hippocampus increases prostaglandin E(2) extracellular levels and triggers lipid peroxidation through cyclooxygenase‐mediated mechanisms. J Neurochem 81:1028–1034. [DOI] [PubMed] [Google Scholar]
  • 109. Perez‐Sala D, Cernuda‐Morollon E, Canada FJ (2003) Molecular basis for the direct inhibition of AP‐1 DNA binding by 15‐deoxy‐Delta 12,14‐prostaglandin J2. J Biol Chem 278:51251–51260. [DOI] [PubMed] [Google Scholar]
  • 110. Perez‐Sala D, Cernuda‐Morollon E, Pineda‐Molina E, Canada FJ (2002) Contribution of covalent protein modification to the antiinflammatory effects of cyclopentenone prostaglandins. Ann N Y Acad Sci 973:533–536. [DOI] [PubMed] [Google Scholar]
  • 111. Petrova TV, Akama KT, Van Eldik LJ (1999) Cyclopentenone prostaglandins suppress activation of microglia: down‐regulation of inducible nitric‐oxide synthase by 15‐deoxy‐Delta 12,14‐prostaglandin J2. Proc Natl Acad Sci U S A 96:4668–4673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 112. Pratico D, Clark CM, Lee VM, Trojanowski JQ, Rokach J, FitzGerald GA (2000) Increased 8,12‐iso‐iPF2alpha‐VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol 48:809–812. [PubMed] [Google Scholar]
  • 113. Qin ZH, Wang Y, Chen RW, Wang X, Ren M, Chuang DM, Chase TN (2001) Prostaglandin A(1) protects striatal neurons against excitotoxic injury in rat striatum. J Pharmacol Exp Ther 297:78–87. [PubMed] [Google Scholar]
  • 114. Ratan RR, Murphy TH, Baraban JM (1994) Oxidative stress induces apoptosis in embryonic cortical neurons. J Neurochem 62:376–379. [DOI] [PubMed] [Google Scholar]
  • 115. Reich EE, Markesbery WR, Roberts LJ, 2nd , Swift LL, Morrow JD, Montine TJ (2001) Brain regional quantification of F‐ring and D‐/E‐ring isoprostanes and neuroprostanes in Alzheimer's disease . Am J Pathol 158:293–297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 116. Reich EE, Montine KS, Gross MD, Roberts LJ, 2nd , Swift LL, Morrow JD, Montine TJ (2001) Interactions between apolipoprotein E gene and dietary alpha‐tocopherol influence cerebral oxidative damage in aged mice. J Neurosci 21:5993–5999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 117. Reich EE, Zackert WE, Brame CJ, Chen Y, Roberts LJ, 2nd , Hachey DL, Montine TJ, Morrow JD (2000) Formation of novel D‐ring and E‐ring isoprostane‐like compounds (D4/E4‐ neuroprostanes) in vivo from docosahexaenoic acid. Biochemistry 39:2376–2383. [DOI] [PubMed] [Google Scholar]
  • 118. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK (1998) The peroxisome proliferator‐activated receptor‐gamma is a negative regulator of macrophage activation. Nature 391:79–82. [DOI] [PubMed] [Google Scholar]
  • 119. Roberts LJ, 2nd , Montine TJ, Markesbery WR, Tapper AR, Hardy P, Chemtob S, Dettbarn WD, Morrow JD (1998) Formation of isoprostane‐like compounds (neuroprostanes) in vivo from docosahexaenoic acid . J Biol Chem 273:13605–13612. [DOI] [PubMed] [Google Scholar]
  • 120. Rohn TT, Wong SM, Cotman CW, Cribbs DH (2001) 15‐deoxy‐delta 12,14‐prostaglandin J2, a specific ligand for peroxisome proliferator‐activated receptor gamma, induces neuronal apoptosis. Neuroreport 12:839–843. [DOI] [PubMed] [Google Scholar]
  • 121. Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, Karin M, Santoro MG (2000) Anti‐inflammatory cyclopentenone prostaglandins are direct inhibitors of I kappaB kinase. Nature 403:103–108. [DOI] [PubMed] [Google Scholar]
  • 122. Rovin BH, Lu L, Cosio A (2001) Cyclopentenone prostaglandins inhibit cytokine‐induced NF‐kB activation and chemokine production by human mesangial cells. J Amer Soc Nephrol 12:1659–1667. [DOI] [PubMed] [Google Scholar]
  • 123. Sairanen T, Ristimaki A, Karjalainen‐Lindsberg ML, Paetau A, Kaste M, Lindsberg PJ (1998) Cyclooxygenase‐2 is induced globally in infarcted human brain. Ann Neurol 43:738–747. [DOI] [PubMed] [Google Scholar]
  • 124. Skinner ER, Watt C, Besson JA, Best PV (1993) Differences in the fatty acid composition of the grey and white matter of different regions of the brains of patients with Alzheimer's disease and control subjects. Brain 116:717–725. [DOI] [PubMed] [Google Scholar]
  • 125. Smith SA, Monteith GR, Holman NA, Robinson JA, May FJ, Roberts‐Thomson SJ (2003) Effects of peroxisome proliferator‐activated receptor gamma ligands ciglitazone and 15‐deoxy‐delta 12,14‐prostaglandin J2 on rat cultured cerebellar granule neuronal viability. J Neuroscience Res 72:747–755. [DOI] [PubMed] [Google Scholar]
  • 126. Stanciu M, Wang Y, Kentor R, Burke N, Watkins S, Kress G, Reynolds I, Klann E, Angiolieri MR, Johnson JW, DeFranco DB (2000) Persistent activation of ERK contributes to glutamate‐induced oxidative toxicity in a neuronal cell line and primary cortical neuron cultures. J Biol Chem 275:12200–12206. [DOI] [PubMed] [Google Scholar]
  • 127. Stewart WF, Kawas C, Corrada M, Metter EJ (1997) Risk of Alzheimer's disease and duration of NSAID use. Neurology 48:626–632. [DOI] [PubMed] [Google Scholar]
  • 128. Straus DS, Glass CK (2001) Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev 21:185–210. [DOI] [PubMed] [Google Scholar]
  • 129. Straus DS, Pascual G, Li M, Welch JS, Ricote M, Hsiang CH, Sengchanthalangsy LL, Ghosh G, Glass CK (2000) 15‐deoxy‐delta 12,14‐prostaglandin J2 inhibits multiple steps in the NF‐ kappa B signaling pathway. Proc Natl Acad Sci U S A 97:4844–4849. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 130. Tan S, Sagara Y, Liu Y, Maher P, Schubert D (1998) The regulation of reactive oxygen species production during programmed cell death. J Cell Biol 141:1423–1432. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 131. Teismann P, Ferger B (2001) Inhibition of the cyclooxygenase isoenzymes COX‐1 and COX‐2 provide neuroprotection in the MPTP‐mouse model of Parkinson's disease. Synapse 39:167–174. [DOI] [PubMed] [Google Scholar]
  • 132. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, Vila M, Jackson‐Lewis V, Przedborski S (2003) Cyclooxygenase‐2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci U S A 100:5473–5478. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 133. van Iersel ML, Cnubben NH, Smink N, Koeman JH, van Bladeren PJ (1999) Interactions of prostaglandin A2 with the glutathione‐mediated biotransformation system. Biochem Pharmacol 57:1383–1390. [DOI] [PubMed] [Google Scholar]
  • 134. Wang X, Qin ZH, Leng Y, Wang Y, Jin X, Chase TN, Bennett MC (2002) Prostaglandin A1 inhibits rotenone‐induced apoptosis in SH‐SY5Y cells. J Neurochem 83:1094–1102. [DOI] [PubMed] [Google Scholar]
  • 135. Wang X, Zhao X, Mao ZY, Wang XM, Liu ZL (2003) Neuroprotective effect of docosahexaenoic acid on glutamate‐induced cytotoxicity in rat hippocampal cultures. Neuroreport 14:2457–2461. [DOI] [PubMed] [Google Scholar]
  • 136. Willoughby DA, Moore AR, Colville‐Nash PR (2000) Cyclopentenone prostaglandins‐new allies in the war on inflammation. Nat Med 6:137–138. [DOI] [PubMed] [Google Scholar]
  • 137. Yasojima K, Tourtellotte WW, McGeer EG, Mc‐Geer PL (2001) Marked increase in cyclooxygenase‐2 in ALS spinal cord: implications for therapy. Neurology 57:952–956. [DOI] [PubMed] [Google Scholar]
  • 138. Yokoyama Y, Saito M, Saito T, Yuguchi T, Sawataishi M, Sakamoto T, Tazawa K, Tsukada K (2000) Synergistic antiproliferative effect of delta 12‐prostaglandin J2 (delta 12‐PGJ2) and hyperthermia on human esophageal cancer cell lines. Hum Cell 13:23–33. [PubMed] [Google Scholar]
  • 139. Zandi PP, Anthony JC, Hayden KM, Mehta K, Mayer L, Breitner JC (2002) Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology 59:880–886. [DOI] [PubMed] [Google Scholar]
  • 140. Zanoni G, Porta A, Castronovo F, Vidari G (2003) First total synthesis of J(2) isoprostane. J Organic Chem 68:6005–6010. [DOI] [PubMed] [Google Scholar]
  • 141. Zanoni G, Porta A, Vidari G (2002) First total synthesis of A(2) isoprostane. J Org Chem 67:4346–4351. [DOI] [PubMed] [Google Scholar]
  • 142. Zusman RM, Caldwell BV, Speroff L, Behrman HR (1972) Radioimmunoassay of the A prostaglandins. Prostaglandins 2:41–53. [DOI] [PubMed] [Google Scholar]

Articles from Brain Pathology are provided here courtesy of Wiley

RESOURCES